Journal article

Economic Evaluation of Population-BasedBRCA1/BRCA2Mutation Testing across Multiple Countries and Health Systems

Ranjit Manchanda, Li Sun, Shreeya Patel, Olivia Evans, Janneke Wilschut, Ana Carolina De Freitas Lopes, Faiza Gaba, Adam Brentnall, Stephen Duffy, Bin Cui, Patricia Coelho De Soarez, Zakir Husain, John Hopper, Zia Sadique, Asima Mukhopadhyay, Li Yang, Johannes Berkhof, Rosa Legood

Cancers | MDPI | Published : 2020

Abstract

Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA carriers who can benefit from screening/prevention. We estimate the cost-effectiveness of population-based BRCA testing in general population women across different countries/health systems. A Markov model comparing the lifetime costs and effects of BRCA1/BRCA2 testing all general population women ≥30 years compared with clinical criteria/FH-based testing. Separate analyses are undertaken for the UK/USA/Netherlands (high-income countries/HIC), China/Brazil (upper-middle income countries/UMIC) and India (low-middle income countries/LMIC) using both health system/payer and societal perspectives. BRCA carriers..

View full abstract

Grants

Awarded by Barts Cancer Research UK Centre for Excellence, Queen Mary University of London


Funding Acknowledgements

We are grateful to Melissa Southey (Monash University, Australia) for her support of this work. The study is supported by researchers at the Barts Cancer Research UK Centre for Excellence, Queen Mary University of London (C16420/A18066). This study/analysis received full ethics approval from the Institute of Child Health/ Great Ormond Street Hospital Research Ethics Committee on (REC Reference number 08/H0713/44, Substantial Amendment 3/7/2018).